Therefore these three factors and beta-2-microglobulin, age and clinical stage are implemented into the CLL-IPI, an international prognostic impact informative for TTFT, PFS and OS in CLL [15]. This evidence concerns the gene B2M and B-cell chronic lymphocytic leukemia.